NEW YORK (GenomeWeb News) – Laboratory Corporation of America after the close of the market on Tuesday reaffirmed its revenue guidance for full-year 2013 and trimmed the low end of its adjusted EPS.

The company also provided preliminary guidance for full-year 2014.

Revenues for 2013 were reaffirmed at a growth rate of 3 percent, while adjusted EPS was changed to a range of $6.90 to $7.05 from a prior range of $6.95 to $7.05.

For full-year 2014, LabCorp gave preliminary guidance of 2 percent revenue growth and $6.50 in non-GAAP EPS, excluding amortization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.